Turse Erica P, Dailey Francis E, Naseer Maliha, Partyka Edward K, Tahan Veysel
Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Missouri Health Center, Columbia, MO 65212, United States.
World J Clin Cases. 2018 Oct 26;6(12):493-500. doi: 10.12998/wjcc.v6.i12.493.
Patients with fistulizing inflammatory bowel disease are traditionally difficult to treat. This patient population often experiences delayed or insufficient healing of fistulas using current standard regimens including antibiotics, immunomodulators, anti-tumor necrosis factor-α drug, placement of setons, and surgical repair. Several studies over the last ten to fifteen years have been conducted using stem cell therapies with promising results in this patient population. These studies show stem cell therapy in fistulizing disease to be successful in healing between 60%-88% compared to currently 50% with infliximab. Moreover, remission was seen 24 wk to 52 wk in these studies. Further research with a multi-approach treatment using medications, stem cell therapy, and surgical interventions will likely be the future of this innovative treatment approach.
传统上，瘘管性炎症性肠病患者很难治疗。使用包括抗生素、免疫调节剂、抗肿瘤坏死因子-α药物、放置引流管和手术修复在内的当前标准治疗方案，这一患者群体的瘘管愈合常常延迟或不充分。在过去的十到十五年里，已经开展了几项使用干细胞疗法的研究，在这一患者群体中取得了令人鼓舞的结果。这些研究表明，与目前英夫利昔单抗50%的治愈率相比，干细胞疗法在瘘管性疾病中的治愈率为60%-88%。此外，在这些研究中，24周-52周时可见缓解。使用药物、干细胞疗法和手术干预的多方法治疗的进一步研究可能是这种创新治疗方法的未来。
